CD19 and mantle cell lymphoma: Brexucabtagene autoleucel is anti-CD19 CAR-T cell therapy commercially known as TECARTUSTM and is indicated for the treatment of adult patients either with r/r mantle cell lymphoma (MCL) or ALL (48).